CORT: Corcept Therapeutics Incorporated - Summary | Jitta

Corcept Therapeutics Incorporated

NASDAQ:CORT

Price
$17.61
Loss Chance
40.4%
6.65JITTA SCORE
41.53%Under Jitta Line
Jitta Ranking
5 / 1,132
113 / 4,789
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (73)
Recent Business Performance (51)
Financial Strength (93)
Return to Shareholders (49)
Competitive Advantage (64)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Operating MarginExpansion
Debt LevelLow Long Term Debt
Return on EquityConsistently High
CapExVery Low
SG&A to SalesDecreasing
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2015
Key Stats
Jitta Score
Jitta Line
6.65
41.53%
1.98
110.36%
2.12
259.55%
Pharmaceuticals
5.66
20.27%
5.79
0.47%
4.37
67.32%
COMPANY DESCRIPTION
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.